



May 19, 2024

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: U.S. FDA Inspection of the Company's Somerset manufacturing facility

We would like to inform you that the U.S. FDA concluded a Pre Approval Inspection at Lupin's Somerset, New Jersey manufacturing facility. The inspection was conducted from May 7, 2024 to May 17, 2024, and closed with an issuance of a Form-483 with six observations.

We are addressing the observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)